XLO News and Press, Xilio Therapeutics Inc. From 10/31/23

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and we...

2023-10-06 18:38:52 ET Summary AGEN has chosen to focus its efforts on botensilimab and balstilimab, postponing its other clinical and preclinical programs. A 25% workforce reduction and focus on its most promising pipeline members will help to save ~$40M in costs through the end ...

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced upcoming poster presentations at the Society for Im...

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the promotion of Katarina Luptakova, M.D., to the r...

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive off...

2023-08-14 09:57:55 ET Xilio Therapeutics press release ( NASDAQ: XLO ): Q2 GAAP EPS of -$0.70. Cash and cash equivalents were $75.4 million as of June 30, 2023, compared to $120.4 million as of December 31, 2022. For further details see: Xilio Therapeutics GAAP ...

Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with microsatellite stable (MSS) colorectal cancer Xilio to host live virtual program spotlighting X...

2023-08-03 16:32:54 ET Xilio Therapeutics Inc ( NASDAQ: XLO ) on Thursday promoted Chris Frankenfield to chief operating officer. Prior to becoming chief operating officer, Frankenfield served as Xilio’s chief legal and administrative officer and as general counsel. ...

2023-08-01 15:49:41 ET Summary MDNA failed to report data from the fifth dosing cohort, of its phase 1/2 ABILITY study of MDNA11, in Q2'23 as expected. The company is instead presenting data from both the fifth and sixth cohorts of the trial on August 9, 2023. MDNA has cash to...

2023-07-13 17:25:28 ET Gainers: ACADIA Pharmaceuticals  ( ACAD ) +29% . Intuitive Machines ( LUNR ) +25% . Atara Biotherapeutics ( ATRA ) +5% . Xilio Therapeutics ( XLO ) +5% . Alector ( ALEC ) +3% . Losers: Theseus ...